Endometrial cancer in a patient with rheumatoid arthritis

Background: Rheumatoid arthritis is a chronic, systemic, and autoimmune disease. In patients with rheumatoid arthritis, there is increased risk for site-specific malignancies. The authors present a case of endometrial cancer in a patient with rheumatoid arthritis and a review of the current literature. Case: The patient, a 60-year-old, postmenopausal Greek woman suffering from rheumatoid arthritis, presented with a complaint of abnormal uterine bleeding. She underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymphadenectomy. Histopathology revealed endometrial cancer. The final diagnosis was Stage Ib endometrial cancer endometrioid type. She underwent postoperative adjuvant radiotherapy. She remains without evidence of disease, 16 months after initial surgery. Conclusion: Although the present patient was diagnosed at early-stage disease and remains well 16 months after initial surgery, she needs a multidisciplinary treatment approach in order to achieve prolonged survival.

Rheumatoid arthritis; Endometrial cancer; Surgery; Radiotherapy.

[1] Aletaha D., Neogi T., Silman A., Funovits J., Felson D., Bingham C., 3rd., et al.: “2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative”. Arthritis Rheum., 2010, 62, 2569.

[2] Sangha O.: “Epidemiology of rheumatic diseases”. Rheumatology (Oxford), 2000, 39, 3.

[3] Grassi W., De Angelis R., Lamanna G., Cervini C.: “The clinical features of rheumatoid arthritis”. Eur. J. Radiol., 1998, 27, S18.

[4] Worthington J.: “Investigating the genetic basis of susceptibility to rheumatoid arthritis”. J. Autoimmun., 2005, 25, 16.

[5] Smitten A.L., Simon T.A., Hochberg M.C., Suissa S.: “A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis”. Arthritis Res. Ther., 2008, 10, R45.

[6] Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., et al.: “Risks of solid cancers in patients with rheumatoid

arthritis and after treatment with tumour necrosis factor antagonists”. Ann. Rheum. Dis., 2005, 64, 1421.

[7] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

[8] Hemminki K., Li X., Sundquist K., Sundquist J.: “Cancer risk in hospitalized rheumatoid arthritis patients”. Rheumatology (Oxford), 2008, 47, 698.

[9] Franks A.L., Slansky J,E.: “Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer”. Anticancer Res., 2012, 32, 1119.

[10] Askling J.: “Malignancy and rheumatoid arthritis”. Curr. Rheumatol. Rep., 2007, 9, 421.

[11] Mellemkjaer L., Linet M.S., Gridley G., Frisch M., Moller H., Olsen J.H.: “Rheumatoid arthritis and cancer risk”. Eur. J. Cancer, 1996, 32A, 1753.

[12] Androutsopoulos G., Adonakis G., Tsamantas A., Liosis S., Antonopoulos A., Kourounis G.: “Synchronous primary cancers in a woman with scleroderma: a case report”. Eur. J. Gynaecol. Oncol., 2008, 29, 548.

[13] Androutsopoulos G., Adonakis G., Tsamandas A., Andonopoulos A., Decavalas G.: “Systemic Sclerosis and Multiple Cancers of the Female Genital Tract: Prolonged Survival following Current Treatment Strategies.”. Case. Rep. Rheumatol., 2011, 2011, 392068.

[14] Sorosky J.: “Endometrial cancer”. Obstet. Gynecol., 2012, 120, 383.

[15] Bakkum-Gamez J.N., Gonzalez-Bosquet J., Laack N.N., Mariani A., Dowdy S.C.: “Current issues in the management of endometrial cancer”. Mayo Clin. Proc., 2008, 83, 97.

[16] ACOG: “ACOG practice bulletin #65: management of endometrial cancer”. Obstet. Gynecol., 2005, 106, 413.

[17] Androutsopoulos G.: “Current treatment options in patients with endometrial cancer”. J. Community Med. Health Educ., 2012, 2, e113.

[18] Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I.: “Treatment modalities in endometrial cancer”. Curr. Opin. Oncol., 2007, 19, 479.

[19] Marnitz S., Kohler C.: “Current therapy of patients with endometrial carcinoma. A critical review”. Strahlenther. Onkol., 2012, 188, 12.

[20] Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I.: “Endometrial cancer.” Lancet, 2005, 366, 491.

[21] Creutzberg C., van Putten W., Koper P., Lybeert M., Jobsen J., Warlam- Rodenhuis C., et al.: “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma”. Lancet, 2000, 355, 1404.

[22] Keys H., Roberts J., Brunetto V., Zaino R., Spirtos N., Bloss J., et al.: “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2004, 92, 744.

[23] Kong A., Johnson N., Kitchener H., Lawrie T.: “Adjuvant radiotherapy for stage I endometrial cancer”. Cochrane Database Syst. Rev., 2012, 4, CD003916.

[24] Nout R., Smit V., Putter H., Jurgenliemk-Schulz I., Jobsen J., Lutgens L., et al.: “Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial”. Lancet, 2010, 375, 816.

[25] Chino J., Jones E., Berchuck A., Secord A., Havrilesky L.: “The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2012, 82, 1872.

[26] Hogberg T.: “What is the role of chemotherapy in endometrial cancer?” Curr. Oncol. Rep., 2011, 13, 433.

[27] Fleming G., Brunetto V., Cella D., Look K., Reid G., Munkarah A., et al.: “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2004, 22, 2159.

[28] Dedes K., Wetterskog D., Ashworth A., Kaye S., Reis-Filho J.: “Emerging therapeutic targets in endometrial cancer”. Nat. Rev. Clin. Oncol., 2011, 8, 261.

[29] Konecny G., Santos L., Winterhoff B., Hatmal M., Keeney G.L., Mariani A., et al.: “HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer”. Br. J. Cancer, 2009, 100, 89. [30] Adonakis G., Androutsopoulos G.: “The role of ErbB receptors in endometrial cancer”. In: Saldivar J.S., (ed.). Cancer of the uterine endometrium: advances and controversies: Rijeka: InTech, 2012, 23.

[31] Adonakis G., Androutsopoulos G., Koumoundourou D., Liava A., Ravazoula P., Kourounis G.: “Expression of the epidermal growth factor system in endometrial cancer”. Eur. J. Gynaecol. Oncol., 2008, 29, 450.

[32] Androutsopoulos G., Adonakis G., Liava A., Ravazoula P., Decavalas G.: “Expression and potential role of ErbB receptors in type II endometrial cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2013, 168, 204.

[33] Prat J.: “Prognostic parameters of endometrial carcinoma”. Hum. Pathol., 2004, 35, 649.

[34] Ji J., Liu X., Sundquist K., Sundquist J.: “Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer”. Rheumatology (Oxford), 2011, 50, 1513.